전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
netherlands | zbigniew wolny
pays-bas | zbigniew wolny
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
j. michael adams, cedefop dagmar wolny, cedefop responsible for translation:
les participants ont estimé que cette distinction devait être établie sur la base des différentes certifications et non sur celle des établissements qui dispensent les formations.
마지막 업데이트: 2014-02-06
사용 빈도: 1
품질:
coordination: j. michael adams, corinna frey, dagmar wolny responsible for translation: david crabbe
service traduction: sylvie bousquet, cedefop amaryllis weilervassilikioti, cedefop
마지막 업데이트: 2014-02-06
사용 빈도: 1
품질:
agnieszka wolny-hamkało was born in wrocław, poland, in 1979, and has published three anthologies of short stories and six books of poetry.
agnieszka wolny-hamkało (*1979 wrocław, pologne) a publié, entre autres, trois anthologies et six recueils de poésie.
마지막 업데이트: 2018-02-13
사용 빈도: 1
품질:
coordination: bernd möhlmann, cedefop dagmar wolny, cedefop amination or drops out should receive at least a qualification certificate of the skills they had acquired to date.
source: bibb/cedefop/sk soit examinée la possibilité d'utiliser les divers programmes pour établir un lien entre l'emploi et le perfectionnement de la qualification.
마지막 업데이트: 2014-02-06
사용 빈도: 1
품질:
dr. arlene wolny gave novartis's regulatory perspective health canada's issues regarding submissions for adjuvant therapy of hrebc, summarized as follows:
la dre arlene wolny fait part des préoccupations de santé canada liées aux présentations du traitement adjuvant, selon le point de vue réglementaire de novartis, pour le cancer primaire du sein qui réagit aux hormones.
마지막 업데이트: 2015-05-14
사용 빈도: 1
품질:
dr. arlene wolny gave novartis’s regulatory perspective health canada’s issues regarding submissions for adjuvant therapy of hrebc, summarized as follows: • single adequate & well controlled trial is sufficient for regulatory review
la dre arlene wolny fait part des préoccupations de santé canada liées aux présentations du traitement adjuvant, selon le point de vue réglementaire de novartis, pour le cancer primaire du sein qui réagit aux hormones.
마지막 업데이트: 2015-05-14
사용 빈도: 1
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다